BTK and B-cell chronic lymphocytic leukemia: Ultra-deep NGS have shed light on the molecular mechanisms of the acquisition of resistance to a given treatment in CLL, as shown for TP53 mutations under chemoimmunotherapy (71–73), BTK and PLCγ2 mutations under ibrutinib (74–78) and BCL2 mutations under venetoclax (79, 80).